打开APP

默克雪兰诺与Kadimastem达成干细胞药物筛选合作

  1. 默克雪兰诺
  2. Kadimastem
  3. 干细胞
  4. 髓磷脂
  5. 多发性硬化症

来源:生物谷 2013-11-06 07:08

2013年11月6日讯 /生物谷BIOON/ --默克雪兰诺(Merck Serono)和以色列Kadimastem公司签署谅解备忘录(memorandum of understanding),旨在推进双方于2012年达成的干细胞为基础的药物筛选合作。

2013年11月6日讯 /生物谷BIOON/ --默克雪兰诺(Merck Serono)和以色列Kadimastem公司签署谅解备忘录(memorandum of understanding),旨在推进双方于2012年达成的干细胞为基础的药物筛选合作。

Kadimastem公司已开发出了将干细胞分化为少突胶质细胞(oligodendrocytes)的技术,少突胶质细胞是一类脑细胞,能够产生髓磷脂(myelin)。髓磷脂是神经元外侧的脂质,起到保护和绝缘的作用。如果人类中枢神经系统出现故障,这一绝缘脂质就会降解,丧失功效,其中最常见的情况就是多发性硬化症(multiple sclerosis,MS)。

Kadimastem公司和默克雪兰诺已经在利用基于干细胞的药物筛选技术,来发现能够刺激分化和髓鞘形成(myelination)的化合物,这类化合物,有望开发成为MS的新疗法。(生物谷Bioon.com)

英文原文:Merck Serono, Kadimastem collaborate on cell-based drug screening

Nov 4 (Reuters) - Merck Serono and Israel's Kadimastem signed a memorandum of understanding aimed at advancing their stem cell-based drug screening collaboration initiated in 2012, the companies said on Monday.

Kadimastem has developed technologies to differentiate stem cells into oligodendrocytes, which are brain cells that produce myelin, the insulation for the neural wiring.

In multiple sclerosis (MS), oligodendrocytes are destroyed by the immune system. Kadimastem and Merck Serono have been leveraging cell-based drug screening technology to discover compounds that stimulate differentiation and myelination.

Such compounds may lead to new therapeutics for MS, mainly in those stages where current drugs that affect the immune system have no more therapeutic use.

"Kadimastem offers us a unique, human-cell based, screening model allowing us to better identify promising compounds at an earlier stage in development," Annalisa Jenkins, head of global development and medical for Merck Serono, said.

Michel Revel, Kadimastem chief scientific officer and developer of Merck Serono's MS drug Rebif, said he believes Kadimastem's stem cell technologies have tremendous potential for the discovery of new therapeutic agents for neurodegenerative diseases as well as diabetes.

Merck Serono is the biopharmaceutical division of Germany's Merck KGaA. (Reporting by Tova Cohen)

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->